ATE196477T1 - Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon - Google Patents

Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon

Info

Publication number
ATE196477T1
ATE196477T1 AT91904912T AT91904912T ATE196477T1 AT E196477 T1 ATE196477 T1 AT E196477T1 AT 91904912 T AT91904912 T AT 91904912T AT 91904912 T AT91904912 T AT 91904912T AT E196477 T1 ATE196477 T1 AT E196477T1
Authority
AT
Austria
Prior art keywords
monoclonal antibody
hypervariable region
constructs
therapeutic uses
radioisotope
Prior art date
Application number
AT91904912T
Other languages
English (en)
Inventor
David A Scheinberg
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE196477T1 publication Critical patent/ATE196477T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT91904912T 1989-12-14 1990-12-14 Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon ATE196477T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45091889A 1989-12-14 1989-12-14
PCT/US1990/007436 WO1991009058A1 (en) 1989-12-14 1990-12-14 Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof

Publications (1)

Publication Number Publication Date
ATE196477T1 true ATE196477T1 (de) 2000-10-15

Family

ID=23790050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91904912T ATE196477T1 (de) 1989-12-14 1990-12-14 Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon

Country Status (9)

Country Link
US (1) US5730982A (de)
EP (1) EP0504327B1 (de)
JP (1) JPH05503632A (de)
AT (1) ATE196477T1 (de)
AU (1) AU659083B2 (de)
CA (1) CA2072017A1 (de)
DE (1) DE69033631T2 (de)
ES (1) ES2152216T3 (de)
WO (1) WO1991009058A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
ZA932523B (en) * 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
WO1994007138A1 (en) 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
NO180658C (no) 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
NO961031D0 (no) * 1996-03-13 1996-03-13 Det Norske Radiumshospital Tum Fremgangsmåte til å drepe uönskede målceller
US20060073133A1 (en) * 1997-04-02 2006-04-06 Kikly Kristine K Sialoadhesin factor-3 antibodies
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
JP5064608B2 (ja) * 1998-05-26 2012-10-31 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ アルファ粒子放出構成物およびその使用方法
US7736651B1 (en) 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
IT1307826B1 (it) * 1999-12-16 2001-11-19 Dipartimento Di Medicina Speri Metodo diagnostico per il riconoscimento di cellule mieloidi normali eleucemiche, ligandi utilizzati in detto metodo e formulazioni ad uso
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
EP2783700A1 (de) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Auf Krebsstammzellen gerichtete Krebstherapie
US20110038856A1 (en) * 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
EP3307779A2 (de) 2015-06-12 2018-04-18 Alector LLC Anti-cd33-antikörper und verfahren zur verwendung davon
MY205541A (en) 2017-08-03 2024-10-25 Alector Llc Anti-cd33 antibodies and methods of use thereof
US12083192B2 (en) 2017-12-04 2024-09-10 Actinium Pharmaceuticals, Inc. Methods for treatment of patients with myelodysplastic syndromes
AR119259A1 (es) 2018-08-31 2021-12-09 Alector Llc Anticuerpos anti-cd33 y métodos de uso de los mismos
US11666672B2 (en) 2018-11-21 2023-06-06 City Of Hope Anti-CD33 antibody-guided imaging and treatment of acute myeloid leukemia
WO2020123947A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Also Published As

Publication number Publication date
AU659083B2 (en) 1995-05-11
AU7313591A (en) 1991-07-18
DE69033631T2 (de) 2001-05-17
ES2152216T3 (es) 2001-02-01
EP0504327A1 (de) 1992-09-23
EP0504327A4 (en) 1993-06-30
EP0504327B1 (de) 2000-09-20
WO1991009058A1 (en) 1991-06-27
US5730982A (en) 1998-03-24
DE69033631D1 (de) 2000-10-26
CA2072017A1 (en) 1991-06-15
JPH05503632A (ja) 1993-06-17

Similar Documents

Publication Publication Date Title
DE69033631D1 (de) Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon
ATE106750T1 (de) Funktionspezifische antikörper.
DE3479633D1 (en) Immunotoxin conjugates
ATE208820T1 (de) Humanisierte antikoerper
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
ATE155818T1 (de) Nicht glycosylierter anti-cd3-igg-antikörper
FR2601675B1 (fr) Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
NO910923D0 (no) Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel.
GB2301366A (en) Antibodies against E-selectin
IL87885A0 (en) Compounds having antiprogestational and anti-estrogenic activities for the treatment of tumours
DE68912334D1 (de) Immunokonjugate für krebs-diagnose und -therapie.
NO166267C (no) Konjugat av et maalsoekende biologisk aktivt molekyl og en forbindelse inneholdende spormerkende metall, samt diagnostisk preparat inneholdende konjugatet.
EP0141079A3 (en) Monoclonal antibodies specific for membrane-associated antigens
ATE248859T1 (de) Metallion-ligand koordinationskomplexe, antikorper dagegen und tests die solche antikorper verwenden
ES2116789T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y empleo.
DE69128273D1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
ATE164078T1 (de) Antikörperkonjugate für die behandlung neoplastischer krankheiten
OA04205A (fr) L'exclusion (anti-aliasing) des fréquences spatiales au moyen du placement de geophones et de sources.
ATE90332T1 (de) Verbindung, zusammensetzung, verfahren und anwendung.
FI853389L (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
ATE122895T1 (de) Monoklonale antikörper gegen den interleukin 2- rezeptor.
ES2093135T3 (es) Anticuerpos monoclonales contra el complejo plasmina-antiplasmina, procedimiento para su preparacion asi como su utilizacion.
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
TWI265811B (en) Extended type 1 chain glycosphingolipids as tumor-associated antigens

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time